Next Article in Journal
Who’s on Call? Mandibular Fracture Management at a Level I Trauma Center
Previous Article in Journal
The Duration of Proton Pump Inhibitor Therapy and the Risk of Small Intestinal Bacterial Overgrowth: A Systematic Review and Meta-Analysis
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

An Analysis of the Role of Bisphenol A in Breast and Reproductive-System Cancers

1
Students’ Scientific Club of Pathophysiologists, Department of Human Physiology and Pathophysiology, School of Medicine, University of Warmia and Mazury in Olsztyn, 10-082 Olsztyn, Poland
2
Department of Anatomy and Histology, School of Medicine, Collegium Medicum, University of Warmia and Mazury in Olsztyn, 10-082 Olsztyn, Poland
3
Clinical Hospital of Ministry of Interior with Warmia-Mazury Cancer Center, 10-228 Olsztyn, Poland
4
School of Public Health, Center of Medical Postgraduate Education, 00-416 Warsaw, Poland
5
Department of Medical Biology, Faculty of Health Sciences, University of Warmia and Mazury in Olsztyn, 10-561 Olsztyn, Poland
6
Department of Gynecology and Obstetrics, School of Medicine, Collegium Medicum, University of Warmia and Mazury, 10-045 Olsztyn, Poland
7
Department of Clinical Physiology, Faculty of Veterinary Medicine, University of Warmia and Mazury in Olsztyn, Oczapowskiego 13, 10-718 Olsztyn, Poland
8
Department of Human Physiology and Pathophysiology, School of Medicine, Collegium Medicum, University of Warmia and Mazury in Olsztyn, 10-082 Olsztyn, Poland
*
Authors to whom correspondence should be addressed.
J. Clin. Med. 2025, 14(13), 4706; https://doi.org/10.3390/jcm14134706
Submission received: 9 May 2025 / Revised: 17 June 2025 / Accepted: 30 June 2025 / Published: 3 July 2025
(This article belongs to the Section Oncology)

Simple Summary

Bisphenol A is a chemical commonly used in plastic products such as food containers, bottles, and packaging. Because its structure is similar to that of natural estrogen, it may interfere with hormonal balance in the human body. Some researchers believe that long-term exposure to BPA may increase the risk of developing certain types of cancer, especially those related to hormones. In this study, we examined women with breast cancer and cancer of the reproductive system to see if they had higher levels of BPA in their blood serum. We also asked participants about daily habits that might affect exposure to this chemical. Our results showed that women with cancer had higher levels of BPA compared to healthy individuals; in addition, certain behaviors relating to activities such as food storage and preparation were more common in these groups. These findings suggest a possible link between lifestyle habits, BPA exposure, and hormone-related cancers.

Abstract

Background/Objectives: Bisphenol A (BPA) is an organic compound used in producing polycarbonates and epoxy resins found in products such as food containers, disposable bottles, CDs, and DVDs. Its structure resembles that of endogenous estrogen, which classifies BPA as an endocrine-disrupting chemical (EDC). BPA has been associated with various health abnormalities, including cancer and reproductive system cancer. In this study, we examine the association between BPA exposure, BPA levels in blood serum, and the occurrence of breast cancer and reproductive system cancer. Methods: A total of 84 females were included in this cross-sectional study. All participants completed a questionnaire assessing BPA exposure and underwent a blood test to measure BPA levels in serum. Results: Analysis of the lifestyle questionnaire revealed behavioral differences potentially associated with BPA exposure. A statistically significant difference was observed for responses to Question 13, related to food preparation methods, while responses to Questions 5, 6, and 17 showed trends approaching statistical significance in cancer groups. Serum BPA concentrations were significantly higher in patients with reproductive system cancer compared to the control group (p = 0.045), while a non-significant trend was observed between breast cancer patients and patients with reproductive system cancer (p = 0.0884). Conclusions: In summary, our study demonstrated significantly elevated serum BPA levels in patients with reproductive system cancer compared to controls. These results suggest the hypothesis that higher exposure to BPA may influence or be associated with the development of estrogen-dependent cancers such as breast and endometrial cancer. However, due to the cross-sectional design of the study, causality cannot be established, and further longitudinal studies are warranted.

1. Introduction

Bisphenol A (BPA, 2,2-Bis(4-hydroxyphenyl) propane) is an organic compound from the phenol group which is used to produce plastics. BPA is utilized in the manufacture of polycarbonates (PCs) and epoxy resins [1]. PCs are a group of polymers used to produce items such as food contact materials, disposable bottles, plastic containers, can coatings, CDs, DVDs, electronic housings, and household appliances [2,3]. The main source of human exposure to BPA is food, specifically through migration of this compound from packaging into food products. The main sources of BPA are plastics used for packaging of food and beverage products and for the lining of cans [4]. Experiments have shown that BPA in canned products accumulates mainly in solid portions of food rather than in liquids [5]. Household dust has been found to contain bisphenol A, suggesting that exposure to this compound may also occur via inhalation of intoxicated air and dust [6,7].
Moreover, BPA’s structure closely resembles that of estrogen to the extent that it is often referred to as synthetic estrogen. Long-term observation of the effects of BPA has made it one of the most frequently studied endocrine-disrupting chemicals (EDCs) [8,9]. Xenoestrogens, which are among the EDCs, are substances of natural or synthetic origin that harm the endocrine system by disrupting the production of endogenous hormones and the normal functioning of hormonal axes [10]. BPA is compatible with nuclear estrogen receptors (ERα and Erβ) and also binds to membrane estrogen receptors (mERs) and G protein-coupled receptors (GPR30 and GPER). Additionally, it exhibits antagonistic activity toward thyroid hormone (thyroxin) receptors as well as a moderate anti-androgenic potential [9]. Disruption of the body’s hormonal balance leads to various abnormalities, and BPA’s ability to mimic estrogens contributes to the development of estrogen-dependent cancers such as breast cancer, endometrial cancer type 1, and ovarian cancer [11]. It has been shown that fetal exposure to BPA in mice can significantly impact the development of neoplastic lesions, including changes in the mammary gland, potentially increasing susceptibility to breast cancer later in life [12].
Breast cancer is one of the most widespread malignant tumors affecting women, and is the primary cause of death among women of reproductive age. In the female population, the leading locations for cancers remain the breast, colon, lungs, and uterus. In the Polish statistics for 2023, lung cancer continued to be the leading cause of cancer-related deaths in women (18%), ahead of breast cancer (16%). However, when looking at incidence rates, breast cancer ranked first (23%), with lung cancer in second place (9%), uterine cancer in third (7%), and ovarian cancer in sixth (4%). Poland is among the countries whose population faces a high risk of breast cancer, with an increasing trend over time having also being reported [13,14,15]. The occurrence of breast cancer is associated with unhealthy lifestyle habits, environmental influences, and socio-psychological factors. The majority of risk factors for cancer development are modifiable. Estrogens, both endogenous and exogenous, play a significant role in breast cancer development. While the ovaries are the primary source of estrogen, postmenopausal fat tissue also produces small amounts, with higher levels of body fat increasing estrogen exposure and breast cancer risk. Hormone replacement therapy (HRT) and oral contraceptives further contribute to estrogen-related risk, with studies showing elevated breast cancer incidence among users, though the risk decreases after discontinuation [16]. Reproductive system cancers, such as endometrial cancer type 1 and ovarian cancer, are estrogen-dependent. Due to BPA’s ability to mimic estrogen and act as a so-called “endocrine disruptor”, it is suggested that BPA may contribute to the development of these cancer types as well. It is also suggested that BPA may influence the development of type 1 endometrial cancer through indirect stimulation of abnormal proliferation of endometrial cells [17]. The latest studies highlight the potential role of BPA in affecting the cellular and non-cellular components surrounding the tumor which form the so-called tumor microenvironment (TME) which strongly affects tumor progression and metastasis [11].
BPA has been detected in various human and animal tissues and bodily fluids, including blood serum, urine, saliva, and the mammary gland. However, exposure to BPA among residents of the Warmian–Masurian voivodeship in Poland has not yet been studied. Therefore, this project aimed to assess BPA levels in the blood serum of clinically healthy patients and compare them with the levels found in patients suffering from breast and reproductive system cancer. Furthermore, we aimed to compare the results of a survey assessing each patient’s exposure to BPA with incidence rates for the aforementioned cancers.

2. Materials and Methods

2.1. Study Setting and Patients

We performed a cross-sectional study to determine the association between BPA exposure, BPA blood plasma level, and the occurrence of breast and reproductive system cancers (endometrial and ovarian cancers). The study was conducted in the Clinical Hospital of the Ministry of Internal Affairs and Administration with the Warmia-Mazury Oncology Centre in Olsztyn (departments of Gynecologic Oncology and Urogynecology, Breast Subunit), as well as the Oncology and Immuno-oncology Department with the Day Oncology Therapy Unit in the years 2022–2024. A group of patients treated in the aforementioned departments underwent a survey and an examination of BPA levels in blood serum.
All participants provided their informed consent before their inclusion in the study. The study included a structured 23-item questionnaire developed by the authors to assess dietary habits, food packaging preferences, and environmental exposure to plastic-related materials (Table 1).
Each affirmative answer scored one point. The questions covered various aspects of lifestyle potentially related to BPA exposure, including frequency of processed food intake, use of plastic containers, consumption of canned food, drinking habits involving plastic or metal packaging, cleaning habits, and having a CD/DVD collection. We conducted face-to-face interviews with patients to ensure that each survey was completed correctly. Patients’ weights and heights were measured, and BMI was calculated. Vital signs were checked including blood pressure. In addition to the survey-based assessment, blood samples were collected from all patients.

2.2. Blood Sample Collection

Blood samples were collected from all study participants using standard venipuncture techniques. Blood was drawn into sterile, additive-free Vacutainer tubes to ensure sample integrity. Immediately after collection, the tubes were kept at room temperature for 30 min to allow clot formation.
Following coagulation, the blood samples were centrifuged at 3000 rpm for 10 min at 4 °C to separate the serum. The obtained serum was then carefully aliquoted into sterile microtubes and stored at −80 °C until further ELISA testing. This procedure ensured the stability of BPA levels for subsequent quantification.

2.3. Enzyme-Linked Immunosorbent Assay

The measurement of Estrogen BPA Environmental in plasma was measured using a commercially available Estrogen BPA Environmental ELISA Kit (Abcam, ab175820, Cambridge, UK). The procedure was carried out strictly according to the manufacturer’s protocol. Samples and standards were plated in duplicate. The calculations were made according to the determined curve and formula.

2.4. Statistical Analysis

Statistical analysis was performed in GraphPad Prism version 8 and also in MedCalc version 23.1.3. A p-value of less than 0.05 was considered statistically significant. The analysis of the distribution allowed the selection of the appropriate test. Analyses were performed using one-way ANOVA with Tukey’s post hoc test, Student’s t-test, or nonparametric equivalents.

3. Results

3.1. Patients’ Characteristics

The study included 84 female patients, classified into three groups: control (CTRL; n = 29), breast cancer (n = 37), and reproductive system cancer (n = 18). All participants were women. Ages ranged from 32 to 80 years, with a mean age of 56.55 years. Patients’ demographic and anthropometric data divided into CTRL, breast cancer, and reproductive system cancer groups are presented in Figure 1.
As shown in the figure, there were statistically significant differences in the ages of participants across groups. Women with breast cancer were significantly older than women in the CTRL group and women in the reproductive system cancer group (p < 0.01 and p < 0.05, respectively). No significant differences were observed among the groups in terms of height, body weight, BMI, waist circumference, or health-related points. Similarly, systolic and diastolic blood pressure values did not differ significantly between the studied groups.

3.2. Questionnaire-Based Analysis of Patient Lifestyle and Environmental Exposure

Lifestyle and environmental exposure were assessed using a 23-question survey. The frequency of affirmative responses (scored as 1 point each) was compared across patient groups: CTRL, breast cancer, and reproductive system cancer.
The results of the questionnaire-based analysis are summarized in Table 2, which compares the frequencies of affirmative responses to each question given by individuals in the CTRL group, the breast cancer group, and the reproductive system cancer group. Odds ratios (ORs), 95% confidence intervals (CIs), and p-values were calculated using the CTRL group as the reference category.
Among the analyzed parameters, no statistically significant differences were observed in the prevalence of self-reported hypertension between groups. Hypertension was reported by 37.93% of women in the CTRL group, 56.76% in the breast cancer group, and 38.89% in the reproductive system cancer group. Although the prevalence appeared higher among patients with breast cancer, this difference did not reach statistical significance (OR = 1.0413, 95% CI: 0.3110–3.4871, p = 0.1313).
Among the questionnaire items, the majority of responses did not significantly differ between groups. However, patients diagnosed with breast cancer were significantly less likely to answer affirmatively to Question 13, which addressed the use of specific food preparation methods (e.g., frying or grilling), compared to the CTRL group (24.32% vs. 48.28%; OR = 0.3444, 95% CI: 0.1210–0.9804, p = 0.0458). This finding may suggest differences in dietary habits that warrant further investigation. In addition, a borderline trend toward statistical significance was observed for Question 5, which concerned the frequency of eating in fast-food restaurants. Patients with reproductive system cancer were more likely to report this practice compared to controls (27.78% vs. 6.9%; OR = 5.1923, 95% CI: 0.8859–30.4317, p = 0.0679), indicating a potential link to increased exposure to endocrine-disrupting compounds. Similarly, affirmative responses to Question 6, regarding buying fruits and vegetables in plastic bags, showed a lower frequency among breast cancer patients compared to controls (8.11% vs. 24.14%, OR = 0.2773, 95% CI: 0.0647–1.1881, p = 0.0840), while affirmative responses to Question 17, asking whether water from a plastic bottle accounted for more than 1 L of daily fluid intake, showed a higher frequency in the breast cancer group than in controls (51.35% vs. 27.59%, OR = 2.7708, 95% CI: 0.9807–7.8285, p = 0.0544).
Differences between groups in their responses to certain questions exhibited trends which approached statistical significance (Questions 5, 6, 13, and 17). Several additional trends were also observed. For example, to Question 16, which addressed not paying attention to the chemical composition of food storage containers, women with reproductive system cancer were less likely to respond affirmatively compared to the CTRL group (33.3% vs. 58.62%, OR = 0.3529, 95% CI: 0.1034–1.2044, p = 0.0963), indicating a possible behavioral difference that warrants further investigation. No other questionnaire items revealed statistically or near-statistically significant differences between groups. While some odds ratios appeared elevated, particularly for low-frequency responses (e.g., Question 12, OR = 5.0571), the associated confidence intervals were wide and p-values non-significant, limiting the interpretability of these results. Overall, the findings suggested that a few specific behaviors related to food preparation and storage may have differed between cancer and CTRL groups, while most lifestyle factors assessed in the questionnaire appeared similarly distributed.

3.3. Categorical Comparisons Using the Chi-Square Test

To further assess group-level differences in behavioral patterns, a chi-square test (χ2) was performed for each questionnaire item, comparing the distribution of affirmative (“yes”) versus negative (“no”) responses among the CTRL group, breast cancer patients, and reproductive system cancer patients.
Statistically significant differences in response distributions were observed for several questions. Notably, responses to Question 3, which assessed processed food intake frequency, revealed a highly significant difference between the breast cancer and reproductive system cancer groups (χ2 = 38.30, p < 0.0001), indicating a marked disparity in reported behaviors between these two populations. Responses to Question 5, regarding the frequency of eating in fast-food restaurants, showed a significant difference between the same two groups (χ2 = 7.69, p = 0.0055). A significant difference was also found in responses to Question 13, related to food preparation methods (e.g., frying or grilling), between the CTRL and breast cancer groups (χ2 = 4.05, p = 0.0443), reinforcing earlier findings from odds ratio analysis. Finally, responses to Question 17, which referred to water from a plastic bottle accounting for more than 1 L of the daily fluid intake, differed significantly between breast cancer and reproductive system cancer groups (χ2 = 4.15, p = 0.0417), potentially indicating variation in exposure to BPA-containing linings.
In addition to these significant findings, several other items (e.g., Questions 6 and 16) demonstrated p-values approaching significance, suggesting further possible behavioral trends warranting further study. The full results of the chi-square tests are presented in Table 3.
These results, consistent with previous findings obtained using logistic regression, support the presence of behavioral differences between groups in specific areas related to food storage and preparation which may be linked to BPA exposure. While some significant differences were also observed between the two cancer groups, these findings are reported for descriptive purposes only, and are not emphasized in the Discussion or Conclusions, as the primary focus of the study was on differences relative to the healthy CTRL group.

3.4. Serum BPA Concentration

Serum levels of BPA were measured in all participants using ELISA. Due to the non-normal distribution of the data, as confirmed by the Shapiro–Wilk test (p < 0.05 for all groups), non-parametric Mann–Whitney U tests were applied to compare BPA concentrations between groups (Figure 2; Table 4).
Mean BPA concentration was lowest in the CTRL group (28,191.2 pg/mL), second-lowest in the breast cancer group (49,136 pg/mL), and highest in the reproductive system cancer group (95,883.4 pg/mL).
A statistically significant difference in serum BPA levels was found between patients with reproductive system cancer and the CTRL group (p = 0.045), with the former exhibiting a more-than-threefold increase in median BPA concentration. Although patients with breast cancer showed a nearly twofold higher mean BPA level than CTRL, this difference did not reach statistical significance (p = 0.877). The comparison between reproductive system cancer and breast cancer groups also approached significance (p = 0.0884), suggesting a possible trend toward higher BPA exposure in the reproductive cancer group.
These findings support a potential association between elevated serum BPA levels and the presence of hormone-sensitive cancers, particularly in patients with reproductive system malignancies

4. Discussion

This cross-sectional study investigated the relationship between blood serum BPA concentrations and the presence of hormone-sensitive cancers in women. The findings showed that patients with reproductive system cancer exhibited significantly elevated serum BPA levels compared to healthy controls. In addition, those with breast cancer exhibited a nearly twofold increase in BPA levels; however, this result was not statistically significant. These observations align with prior evidence linking BPA, a well-known EDC, to estrogen-dependent malignancies such as estrogen receptor-positive breast cancer, endometrial cancer type 1, and selected subtypes of ovarian cancer, such as low-grade serous and endometrioid tumors [11,18,19,20,21,22]. Behavioral differences captured through the lifestyle questionnaire further support this association. Notably, the increased use of plastic containers and canned foods among cancer patients, particularly those with reproductive cancers, points to possible environmental sources of BPA exposure. Overall, while most differences between the study groups were not statistically significant, selected trends in dietary behavior and food storage practices may suggest behavioral risk patterns associated with BPA exposure. These preliminary findings support the need for larger, longitudinal studies to explore these associations further.
Our findings align with previous research results indicating that dietary intake is the primary source of BPA exposure in the general population [10,23,24]. Although the questionnaire did not isolate exposure categories by source type, variables related to dietary habits—including heating food in plastic (Q13), storing it in plastic packaging (Q14), and consuming bottled drinks (Q17)—were most strongly associated with elevated serum BPA levels based on odds ratios and chi-square tests. These results suggest that dietary intake might be the predominant contributor to systemic BPA burden in this population.
Our study assessed BPA levels directly in blood serum using ELISA. This approach allows for the detection of circulating, biologically active BPA. Our findings revealed significantly elevated serum BPA concentrations in patients with reproductive system cancer compared to healthy controls. Nevertheless, our results showed a trend toward lower levels of BPA in serum harvested from breast cancer patients compared to patients with reproductive system cancer. These results support the hypothesis that internal BPA burden may be linked to the development of hormone-dependent malignancies, potentially through endocrine-disrupting mechanisms. Our findings are consistent with those of previous studies, including a recent investigation conducted in Bangladesh, which demonstrated that serum BPA levels in breast cancer patients were four to seven times higher than in healthy controls, with average values ranging from 17.0 to 34.0 ng/mL compared to 4.0 ng/mL in the CTRL group. That study also reported a statistically significant association between elevated BPA concentrations in blood serum and the severity of cancer-related symptoms [13]. In another study, BPA was detected in urine and breast adipose tissue samples from the studied populations. The higher average BPA concentration in cancer patients compared to non-cancerous individuals suggests that BPA may contribute to an increased risk of breast cancer [25]. This highlights the need for public health initiatives aimed at reducing plastic use and emphasizes the importance of conducting larger studies in diverse population groups [13].
Focusing on the endocrine-disrupting potential of BPA, numerous studies have highlighted its ability to mimic endogenous estrogens. BPA disrupts the hormonal system primarily by interacting with estrogen receptors, leading to dysregulation of estrogen signaling pathways. Beyond its association with cancer, BPA has been shown to induce early onset of puberty, affect reproductive systems in both females and males, and contribute to increased body weight. Mechanistically, BPA interacts with estrogen-related receptors (ERRs), binds to cell membrane-associated receptors, modulates the expression of cytochrome P450 genes, alters estradiol levels, influences DNA methylation patterns, and activates peroxisome proliferator-activated receptors (PPARs). These multifaceted molecular interactions may contribute to its broad range of physiological and pathological effects [26,27,28]. Exposure to BPA has been associated with the development of several types of cancer, especially those originating in hormone-sensitive tissues, including those of the breast, prostate, testes, ovaries, and endometrium. Early-life BPA exposure in males may disrupt cell growth and migration, increasing the risk of testicular and prostate cancers. BPA has been shown to promote the proliferation and migration of various cell types, including those from the lung, colon, and liver. BPA exposure may activate signaling pathways such as PI3K/Akt and JAK-STAT, and disrupt normal p53 expression, particularly in breast cancer. In addition to its direct effects on tumor cells, BPA can also influence the tumor microenvironment by impairing immune surveillance, potentially accelerating breast cancer progression [29,30]. BPA can bind to classical estrogen receptors (ERα and ERβ), as well as non-classical receptors such as the G-protein-coupled estrogen receptor (GPER), mimicking endogenous estrogens and modulating downstream signaling pathways. This interaction may lead to increased cellular proliferation, inhibition of apoptosis, and altered differentiation in estrogen-sensitive tissues. Additionally, BPA exposure has been linked to epigenetic alterations, including DNA methylation and histone modifications, which can promote oncogenic gene expression patterns [27,31,32]. These observations are supported by several preclinical studies that demonstrate the role of BPA in estrogen receptor activation, epigenetic regulation, and tumor progression [33,34,35,36].
The study is limited by its sample size, particularly in the reproductive system cancer subgroup. In addition, its cross-sectional design prevents causative conclusions from being drawn. Although consistent trends are highlighted in the study results, as the questionnaire relied on self-reported data, the possibility cannot be excluded that certain behaviors were underreported or overreported, influencing the observed associations. Nevertheless, these findings underscore the need for public health initiatives focused on reducing BPA exposure, especially among at-risk populations, and encourage further prospective studies to establish causality.

5. Limitations

This study has several limitations. First, there was no age matching between the cancer and CTRL groups, which may have confounded patterns of BPA concentration and lifestyle exposure. The significant age difference between the CTRL and cancer groups also represents a potential confounding factor because BPA exposure and cancer risk may both increase with age. This limitation should be taken into account when interpreting the observed associations. Second, the study’s cross-sectional design limited the ability to infer causality between BPA levels and cancer incidence. Third, the relatively small sample size in the reproductive cancer group (n = 18) reduced statistical power and our ability to detect moderate statistical differences. The triple-negative breast cancer patients (n = 6) may have presented a different cancer biology to that of hormone-positive breast cancer patients. Even though triple-negative breast cancer is not hormone-sensitive, BPA has been shown to cause inflammation and increase ROS formation, contributing to p53 mutation and/or oncogene formation [37]. Because of this, and because of the low number of triple-negative breast cancer patients in our study, we decided to analyze and describe all breast cancer patients together as a single group, rather than subjecting triple-negative breast cancer patients to an independent statistical analysis. Fourth, because behaviors were self-reported, potential reporting biases were introduced. Fifth, the population sample was geographically limited to Poland, potentially affecting generalizability to broader populations. Lastly, no multivariate adjustment was made for potential confounders such as genetic predisposition or other environmental exposures. Despite these limitations, the findings offer preliminary insights into potential associations between BPA exposure and hormone-related cancers, warranting further longitudinal studies.

6. Conclusions

Our study measured blood serum levels of BPA in patients with breast cancer and reproductive system cancer, revealing notably elevated concentrations in both groups compared to healthy controls. These findings support the hypothesis that BPA may contribute to the development of estrogen-dependent cancers, such as breast, endometrial, and certain ovarian cancers. While not all results reached statistical significance, several trends regarding plastic-related habits suggest meaningful behavioral differences between patient groups that may have influenced BPA exposure. However, interpreting exposure patterns based solely on self-reported survey data remains challenging due to confounding factors such as age differences, lifestyle variability, and generational shifts in product use. Younger individuals may have greater exposure to plastics and electronics, yet cancer diagnoses more commonly occur later in life, potentially obscuring clear associations. Importantly, due to the cross-sectional design of the study, causality cannot be inferred. These preliminary results underscore the need for further investigation using larger and age-balanced cohorts. Longitudinal studies in which biomonitoring is integrated with detailed lifestyle assessment will be essential to clarify the role of BPA in the etiology of hormone-related cancers and inform effective public health strategies.

Author Contributions

Conceptualization, M.D. and J.W.; methodology, M.D., K.Z.-W., and M.J.; software, M.D. and K.Z.-W.; validation, M.D., K.Z.-W., and J.W.; formal analysis, M.D., K.Z.-W., and J.W.; investigation, M.D.; resources, M.D.; A.Z., L.D., and M.J., data curation, M.D., K.Z.-W., and J.W.; writing—original draft preparation, M.D.; writing—review and editing, M.D.,K.Z.-W., J.K., M.J., M.T., S.G., and J.W.; visualization, M.D. and K.Z.-W.; supervision, K.Z.-W. and J.W.; project administration, M.D., K.Z.-W., and J.W.; funding acquisition, M.D. and J.W. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Student Grant of the Rector of the University of Warmia and Mazury in Olsztyn, https://uwm.edu.pl/studenci/studencki-grant-rektora, grant no. 6/2020 (accessed on May 2020–June 2024). The publication fee was funded by the Minister of Science under “the Regional Initiative of Excellence Program”.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki, and approved by the Bioethics Committee of the University of Warmia and Mazury in Olsztyn, (approval no. 26/2017, dated 22 June 2017, and no. 5/2021, dated 21 January 2021).

Informed Consent Statement

Written informed consent has been obtained from the patients to publish this paper.

Data Availability Statement

The original contributions presented in the study are included in the article. Further inquiries can be directed to the corresponding authors.

Acknowledgments

Authors would like to thank the Staff of the Department of Histology and Embryology, University of Warmia and Mazury in Olsztyn as well as Clinical Hospital of Ministry of Interior with Warmia-Mazury Cancer Center for their help and support in extraction of BPA from human serum.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:
BPAbisphenol A
EDCendocrine-disrupting chemical
ERRestrogen-related receptor
PCpolycarbonate
PPARperoxisome proliferator-activated receptor

References

  1. Ucheana, I.A.; Ihedioha, J.N.; Njoku, J.B.C.; Abugu, H.O.; Ekere, N.R. Migration of Bisphenol A from Epoxy-Can Malt Drink under Various Storage Conditions and Evaluation of Its Health Risk. Int. J. Environ. Anal. Chem. 2024, 104, 3936–3955. [Google Scholar] [CrossRef]
  2. Wang, X.; Nag, R.; Brunton, N.P.; Siddique, M.A.B.; Harrison, S.M.; Monahan, F.J.; Cummins, E. Human Health Risk Assessment of Bisphenol A (BPA) through Meat Products. Environ. Res. 2022, 213, 113734. [Google Scholar] [CrossRef] [PubMed]
  3. Tsai, W.-T. Human Health Risk on Environmental Exposure to Bisphenol-A: A Review. J. Environ. Sci. Health Part C 2006, 24, 225–255. [Google Scholar] [CrossRef]
  4. Triswindyaningrum, O.I.; Sulistiyani, S.; Darundiati, Y.H. Systematic Review: Impact of Bisphenol-A (BPA) Exposure on Human Health. J. Environ. Health 2025, 17, 85–98. [Google Scholar]
  5. Noonan, G.O.; Ackerman, L.K.; Begley, T.H. Concentration of Bisphenol A in Highly Consumed Canned Foods on the U.S. Market. J. Agric. Food Chem. 2011, 59, 7178–7185. [Google Scholar] [CrossRef]
  6. Wang, W.; Abualnaja, K.O.; Asimakopoulos, A.G.; Covaci, A.; Gevao, B.; Johnson-Restrepo, B.; Kumosani, T.A.; Malarvannan, G.; Minh, T.B.; Moon, H.-B.; et al. A Comparative Assessment of Human Exposure to Tetrabromobisphenol A and Eight Bisphenols Including Bisphenol A via Indoor Dust Ingestion in Twelve Countries. Environ. Int. 2015, 83, 183–191. [Google Scholar] [CrossRef] [PubMed]
  7. Lee, B.; Yoon, H.; Lee, B.; Kim, P.; Moon, H.-B.; Kim, Y. Occurrence of Bisphenols and Phthalates in Indoor Dust Collected from Korean Homes. J. Ind. Eng. Chem. 2021, 99, 68–73. [Google Scholar] [CrossRef]
  8. Li, Y.-J.; Liu, A.-X.; Zeng, J.-Y.; Miao, Y.; Zhang, M.; Liu, X.-Y.; Yang, W.; Li, R.-C.; Zhu, J.-Q.; Liu, C.-J.; et al. Repeated Measurements of Urinary Bisphenol A and Its Analogues in Relation to Sperm DNA Damage. J. Hazard. Mater. 2025, 487, 137157. [Google Scholar] [CrossRef]
  9. vom Saal, F.S.; Vandenberg, L.N. Update on the Health Effects of Bisphenol A: Overwhelming Evidence of Harm. Endocrinology 2021, 162, bqaa171. [Google Scholar] [CrossRef]
  10. Manzoor, M.F.; Tariq, T.; Fatima, B.; Sahar, A.; Tariq, F.; Munir, S.; Khan, S.; Nawaz Ranjha, M.M.A.; Sameen, A.; Zeng, X.-A.; et al. An Insight into Bisphenol A, Food Exposure and Its Adverse Effects on Health: A Review. Front. Nutr. 2022, 9, 1047827. [Google Scholar] [CrossRef]
  11. Kwon, Y. Potential Pro-Tumorigenic Effect of Bisphenol A in Breast Cancer via Altering the Tumor Microenvironment. Cancers 2022, 14, 3021. [Google Scholar] [CrossRef] [PubMed]
  12. Santaliz Casiano, A.; Lee, A.; Teteh, D.; Madak Erdogan, Z.; Treviño, L. Endocrine-Disrupting Chemicals and Breast Cancer: Disparities in Exposure and Importance of Research Inclusivity. Endocrinology 2022, 163, bqac034. [Google Scholar] [CrossRef] [PubMed]
  13. Kabir, T.; Uddin, N.; Islam, M.S.; Sarkar, B.C. ‘BPA (Bisphenol A) Exposure As An Environmental Risk Factor—A Cross Sectional Study on Breast Cancer Among the Bangladeshi Female Population’. J. Environ. Pollut. Hum. Health 2024, 12, 47–52. [Google Scholar]
  14. Ciuba, A. Breast Cancer in Poland-the Urgent Need for Effective Prevention. Fam. Med. Prim. Care Rev. 2024, 26, 107–111. [Google Scholar] [CrossRef]
  15. Didkowska, J.; Barańska, K.; Miklewska, M.J.; Wojciechowska, U. Cancer Incidence and Mortality in Poland in 2023. Biul. Pol. Tow. Onkol. Nowotw. 2024, 9, 87–105. [Google Scholar] [CrossRef]
  16. Obeagu, E.I.; Obeagu, G.U. Breast Cancer: A Review of Risk Factors and Diagnosis. Medicine 2024, 103, e36905. [Google Scholar] [CrossRef]
  17. Aquino, C.I.; Troisi, J.; D’Antonio, A.; Giugliano, L.; Raffone, A.; Sarno, L.; Saccone, G.; Scala, G.; Guida, M. Endometrial Carcinoma and Bisphenol A: A Pilot Case-Control Study. Biomed. J. Sci. Tech. Res 2019, 21, 16073–16079. [Google Scholar]
  18. Pu, H.; Wen, X.; Luo, D.; Guo, Z. Regulation of Progesterone Receptor Expression in Endometriosis, Endometrial Cancer, and Breast Cancer by Estrogen, Polymorphisms, Transcription Factors, Epigenetic Alterations, and Ubiquitin-Proteasome System. J. Steroid Biochem. Mol. Biol. 2023, 227, 106199. [Google Scholar] [CrossRef]
  19. Jamieson, A.; Huvila, J.; Chiu, D.; Thompson, E.F.; Scott, S.; Salvador, S.; Vicus, D.; Helpman, L.; Gotlieb, W.; Kean, S. Grade and Estrogen Receptor Expression Identify a Subset of No Specific Molecular Profile Endometrial Carcinomas at a Very Low Risk of Disease-Specific Death. Mod. Pathol. 2023, 36, 100085. [Google Scholar] [CrossRef]
  20. Clusan, L.; Ferrière, F.; Flouriot, G.; Pakdel, F. A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer. Int. J. Mol. Sci. 2023, 24, 6834. [Google Scholar] [CrossRef]
  21. Yang, P.-J.; Hou, M.-F.; Ou-Yang, F.; Hsieh, T.-H.; Lee, Y.-J.; Tsai, E.-M.; Wang, T.-N. Association between Recurrent Breast Cancer and Phthalate Exposure Modified by Hormone Receptors and Body Mass Index. Sci. Rep. 2022, 12, 2858. [Google Scholar] [CrossRef] [PubMed]
  22. Winz, C.; Suh, N. Understanding the Mechanistic Link between Bisphenol A and Cancer Stem Cells: A Cancer Prevention Perspective. J. Cancer Prev. 2021, 26, 18–24. [Google Scholar] [CrossRef]
  23. Geens, T.; Aerts, D.; Berthot, C.; Bourguignon, J.-P.; Goeyens, L.; Lecomte, P.; Maghuin-Rogister, G.; Pironnet, A.-M.; Pussemier, L.; Scippo, M.-L. A Review of Dietary and Non-Dietary Exposure to Bisphenol-A. Food Chem. Toxicol. 2012, 50, 3725–3740. [Google Scholar] [CrossRef]
  24. Robles-Aguilera, V.; Gálvez-Ontiveros, Y.; Rodrigo, L.; Salcedo-Bellido, I.; Aguilera, M.; Zafra-Gómez, A.; Monteagudo, C.; Rivas, A. Factors Associated with Exposure to Dietary Bisphenols in Adolescents. Nutrients 2021, 13, 1553. [Google Scholar] [CrossRef] [PubMed]
  25. Keshavarz-Maleki, R.; Kaviani, A.; Omranipour, R.; Gholami, M.; Khoshayand, M.R.; Ostad, S.N.; Sabzevari, O. Bisphenol-A in Biological Samples of Breast Cancer Mastectomy and Mammoplasty Patients and Correlation with Levels Measured in Urine and Tissue. Sci. Rep. 2021, 11, 18411. [Google Scholar] [CrossRef]
  26. Ohore, O.E.; Zhang, S. Endocrine Disrupting Effects of Bisphenol A Exposure and Recent Advances on Its Removal by Water Treatment Systems. A Review. Sci. Afr. 2019, 5, e00135. [Google Scholar] [CrossRef]
  27. Ji, H.; Zhu, H.; Wang, Z.; Liang, H.; Chen, Y.; Liu, X.; Yuan, W.; Wu, Q.; Yuan, Z.; Miao, M. Prenatal Bisphenol Analogs Exposure and Placental DNA Hypomethylation of Genes in the PPAR Signaling Pathway: Insights for Bisphenol Analogs’ Effects on Infant Anthropometry. Environ. Res. 2025, 266, 120476. [Google Scholar] [CrossRef] [PubMed]
  28. Gebru, Y.A.; Pang, M.-G. Modulatory Effects of Bisphenol A on the Hepatic Immune Response. Environ. Pollut. 2023, 336, 122430. [Google Scholar] [CrossRef]
  29. Wiszpolska, M.; Lepiarczyk, E.; Maździarz, M.A.; Paukszto, Ł.; Makowczenko, K.G.; Lipka, A.; Łopieńska-Biernat, E.; Makowska, K.; Gonkowski, S.; Correia-de-Sá, P. The Carcinogenic Potential of Bisphenol A in the Liver Based on Transcriptomic Studies. Cancers 2023, 15, 5014. [Google Scholar] [CrossRef]
  30. Focaccetti, C.; Nardozi, D.; Benvenuto, M.; Lucarini, V.; Angiolini, V.; Carrano, R.; Scimeca, M.; Servadei, F.; Mauriello, A.; Mancini, P. Bisphenol-A in Drinking Water Accelerates Mammary Cancerogenesis and Favors an Immunosuppressive Tumor Microenvironment in BALB–Neu T Mice. Int. J. Mol. Sci. 2024, 25, 6259. [Google Scholar] [CrossRef]
  31. Molina, L.; Figueroa, C.D.; Ehrenfeld, P. Bisphenols and Their Interaction with Gper-1: The Invisible Enemy behind Breast Cancer and Its Societal Impact. In Bisphenols—New Environmental, Pathophysiological and Social Perspectives; IntechOpen: London, UK, 2024. [Google Scholar]
  32. Estes, N.R.; Sheeler, C.; Merriam, O. Effects of Bisphenol Compounds on Gene Expression and Cellular Outcomes in MDA-MB-231 Breast Cancer Cells Mediated via the G Protein-Coupled Estrogen Receptor. Cancer Res. 2025, 85, 190. [Google Scholar] [CrossRef]
  33. Salamanca-Fernández, E.; Rodríguez-Barranco, M.; Amiano, P.; Delfrade, J.; Chirlaque, M.D.; Colorado, S.; Guevara, M.; Jimenez, A.; Arrebola, J.P.; Vela, F.; et al. Bisphenol-A Exposure and Risk of Breast and Prostate Cancer in the Spanish European Prospective Investigation into Cancer and Nutrition Study. Environ. Health 2021, 20, 88. [Google Scholar] [CrossRef] [PubMed]
  34. Tarapore, P.; Ying, J.; Ouyang, B.; Burke, B.; Bracken, B.; Ho, S.-M. Exposure to Bisphenol A Correlates with Early-Onset Prostate Cancer and Promotes Centrosome Amplification and Anchorage-Independent Growth in Vitro. PLoS ONE 2014, 9, e90332. [Google Scholar] [CrossRef]
  35. Lang, I.A.; Galloway, T.S.; Scarlett, A.; Henley, W.E.; Depledge, M.; Wallace, R.B.; Melzer, D. Association of Urinary Bisphenol A Concentration with Medical Disorders and Laboratory Abnormalities in Adults. JAMA 2008, 300, 1303–1310. [Google Scholar] [CrossRef] [PubMed]
  36. Bao, W.; Liu, B.; Rong, S.; Dai, S.Y.; Trasande, L.; Lehmler, H.-J. Association between Bisphenol A Exposure and Risk of All-Cause and Cause-Specific Mortality in US Adults. JAMA Netw. Open 2020, 3, e2011620. [Google Scholar] [CrossRef]
  37. Srinivas, U.S.; Tan, B.W.Q.; Vellayappan, B.A.; Jeyasekharan, A.D. ROS and the DNA Damage Response in Cancer. Redox Biol. 2019, 25, 101084. [Google Scholar] [CrossRef]
Figure 1. Demographic and anthropometric characteristics of control (CTRL), breast cancer, and reproductive system cancer groups. Data are expressed as means  ±  SEM; * p ≤ 0.05, ** p ≤ 0.01 (** = 0.0025, * = 0.0417). Values of n per group are as follows: n = 29 in CTRL (control group); n = 37 in breast cancer group; n = 18 in reproductive system cancer group. n values are indicated by dots.
Figure 1. Demographic and anthropometric characteristics of control (CTRL), breast cancer, and reproductive system cancer groups. Data are expressed as means  ±  SEM; * p ≤ 0.05, ** p ≤ 0.01 (** = 0.0025, * = 0.0417). Values of n per group are as follows: n = 29 in CTRL (control group); n = 37 in breast cancer group; n = 18 in reproductive system cancer group. n values are indicated by dots.
Jcm 14 04706 g001
Figure 2. Serum Bisphenol A (BPA) concentrations [pg/mL] in the control group (CTRL), breast cancer group, and reproductive system cancer group. Median values are indicated. Differences were analyzed using the Mann–Whitney U test. Data are expressed as means  ±  SEM; * p  ≤  0.05 (* = 0.045; # = 0.0884). Values of n per group: n = 29 in CTRL (control group), n = 37 in breast cancer group, n = 18 in reproductive system cancer group. n values are indicated by dots.
Figure 2. Serum Bisphenol A (BPA) concentrations [pg/mL] in the control group (CTRL), breast cancer group, and reproductive system cancer group. Median values are indicated. Differences were analyzed using the Mann–Whitney U test. Data are expressed as means  ±  SEM; * p  ≤  0.05 (* = 0.045; # = 0.0884). Values of n per group: n = 29 in CTRL (control group), n = 37 in breast cancer group, n = 18 in reproductive system cancer group. n values are indicated by dots.
Jcm 14 04706 g002
Table 1. List of questions included in the questionnaire used in the study. Each affirmative answer scored one point. Questions covered topics related to dietary habits, food packaging, and BPA exposure risk factors.
Table 1. List of questions included in the questionnaire used in the study. Each affirmative answer scored one point. Questions covered topics related to dietary habits, food packaging, and BPA exposure risk factors.
Question NumberDescription
1A history of obesity in the family.
2Low-calorie diet, calorie deficit currently.
3Frequency of processed food intake.
4Type of processed food (instant soups, instant puddings and kissels, ready-to-eat microwaveable meals, frozen pizzas, casseroles, and dumplings packed in plastic bags)
5Frequency of eating in fast-food restaurants.
6Buying fruits and vegetables in plastic bags.
7Purchasing rice or groats in a cardboard package containing multiple portions in plastic bags, or inside a plastic pouch.
8Type of fish usually consumed.
9Regular intake of yogurts and desserts packaged in plastic containers.
10Regular intake of plastic-bottled milk.
11Regular intake of cheese packaged in plastic containers.
12Consumption of canned food.
13Method of preparing dishes (frying, grilling).
14Storing food in plastic containers.
15Drinks most frequently consumed during the day: mineral water in plastic bottles, soft drinks in bottles, soft drinks or coffee in cans, juices in plastic bottles.
16Not paying attention to the chemical composition of food storage containers.
17Water from a plastic bottle accounting for more than 1 L of daily fluid intake.
18When purchasing drinks in plastic bottles or cans, drinking them directly from the container.
19Frequency of consuming beer in cans (several times a week or more).
20Having a collection of CDs/DVDs consisting of 20 or more copies.
21Vacuuming with an electric vacuum cleaner (several times a week or more).
22Consuming food in restaurants (several times a week or more).
23Ordering a meal-box diet (during working days or on a daily basis).
Table 2. Distribution of patients among study groups and percentages of affirmative responses to individual questionnaire items. Odds ratios (ORs), 95% confidence intervals (CIs), and p-values are shown for comparisons with the control group. Control (CTRL). Reference—reference for OR calculation.
Table 2. Distribution of patients among study groups and percentages of affirmative responses to individual questionnaire items. Odds ratios (ORs), 95% confidence intervals (CIs), and p-values are shown for comparisons with the control group. Control (CTRL). Reference—reference for OR calculation.
Total Number of Patients
Patient groupsCTRL
29/84 (34.52%)
Breast cancer
37/84 (44.05%)
Reproductive system cancer
18/84 (21.43%)
Parameter/questionNumber of patients: n, (%), OR, 95% CI, Z, p-value
Hypertension11/29 (37.93%)reference21/37 (56.76%)OR: 1.0413,
95% CI: 0.3110–3.4871,
Z: 1.509
p = 0.1313
7/18 (38.89%)OR: 1.0413,
95% CI: 0.3110–3.4871,
Z: 0.066
p = 0.9476
118/29 (62.07%)reference25/37 (67.58%)OR: 1.2731,
95% CI: 0.46–3.5239,
Z: 0.465
p = 0.642
10/18 (55.56%)OR: 0.7639,
95% CI: 0.2313–2.5225,
Z: 0.442
p = 0.6586
225/29 (86.2%)reference35/37 (94.6%)OR: 2.8,
95% CI: 0.4754–16.4929,
Z: 1.138
p = 0.2551
15/18 (83.33%)OR: 0.8,
95% CI: 0.1570–4.0753,
Z: 0.269
p = 0.7882
33/29 (10.35%)reference3/37 (8.11%)OR: 0.7647,
95% CI: 0.1425–4.1024,
Z: 0.313
p = 0.7543
1/18 (5.56%)OR: 0.5098,
95% CI: 0.0489–5.3153,
Z: 0.563
p = 0.5732
423/29 (79.31%)reference23/37 (62.16%)OR: 0.4286,
95% CI: 0.1402–1.3102,
Z: 1.486
p = 0.1372
15/18 (83.33%)OR: 1.3043,
95% CI: 0.2822–6.0297,
Z: 0.340
p = 0.7337
52/29 (6.9%)reference1/37 (2.7%)OR: 0.3750,
95% CI: 0.0323–4.3535,
Z: 0.784
p = 0.4330
5/18 (27.78%)OR: 5.1923,
95% CI: 0.8859–30.4317,
Z: 1.826
p = 0.0679
67/29 (24.14%)reference3/37 (8.11%)OR: 0.2773,
95% CI: 0.0647–1.1881,
Z: 1.728
p = 0.0840
3/18 (16.67%)OR: 0.6286,
95% CI: 0.1398–2.8265,
Z: 0.605
p = 0.5450
722/29 (75.86%)reference23/37 (62.16%)OR: 0.5227,
95% CI: 0.1776–1.5382,
Z: 1.178
p = 0.2388
13/18 (72.2%)OR: 0.8273,
95% CI: 0.2173–3.1495,
Z: 0.278
p = 0.781
824/29 (82.76%)reference34/37 (91.9%)OR: 2.3611,
95% CI: 0.5145–10.8364,
Z: 1.105
p = 0.2691
15/18 (83.33%)OR: 1.0417,
95% CI: 0.2167–5.0071,
Z: 0.051
p = 0.9594
929/29 (100%)reference37/37 (100%)OR: 1.2712,
95% CI:
0.0245–65.9908,
Z: 0.119
p = 0.9052
18/18 (100%)OR: 0.6271,
95% CI:
0.0119–32.9913,
Z: 0.231
p = 0.8175
109/29 (31.03%)reference15/37 (40.54%)OR: 1.5152,
95% CI: 0.5439–4.2209,
Z: 0.795
p = 0.4267
8/18 (44.4%)OR: 1.7778,
95% CI: 0.526–6.009,
Z: 0.926
p = 0.3545
1113/29 (44.83%)reference18/37 (48.65%)OR: 1.1660,
95% CI: 0.4397–3.0922,
Z: 0.309
p = 0.7576
11/18 (61.1%)OR: 1.9341,
95% CI: 0.5841–6.4043,
Z: 0.309
p = 0.7576
120/29 (0%)reference2/37 (5.41%)OR: 4.1549,
95% CI: 0.1918–89.9925,
Z: 0.908
p = 0.364
1/18 (5.55%)OR: 5.0571,
95% CI: 0.1951–131.0588,
Z: 0.976
p = 0.3291
1314/29 (48.28%)reference9/37 (24.32%)OR: 0.3444,
95% CI: 0.1210–0.9804,
Z: 1.997
p = 0.0458
9/18 (50%)OR: 1.0714,
95% CI: 0.3304–3.4747,
Z: 0.115
p = 0.9085
1411/29 (37.93%)reference12/37 (32.43%)OR: 0.7855,
95% CI: 0.2838–2.1740,
Z: 0.465
p = 0.642
9/18 (50%)OR: 1.6364,
95% CI: 0.4978–5.3794,
Z: 0.811
p = 0.4173
1525/29 (86.21%)reference32/37 (86.49%)OR: 1.024,
95% CI: 0.2487–4.2156,
Z: 0.033
p = 0.9738
16/18 (88.9%)OR: 1.28,
95% CI: 0.2095–7.8189,
Z: 0.267
p = 0.7892
1617/29 (58.62%)reference19/37 (51.35%)OR: 0.7451,
95% CI: 0.2795–1.9866,
Z: 0.588
p = 0.5565
6/18 (33.3%)OR: 0.3529,
95% CI: 0.1034–1.2044,
Z: 1.663
p = 0.0963
178/29 (27.59%)reference19/37 (51.35%)OR: 2.7708,
95% CI: 0. 0.9807–7.8285,
Z: 1.923
p = 0.0544
4/18 (22.2%)OR: 0.75,
95% CI: 0.1891–2.9742,
Z: 0.409
p = 0.6823
1810/29 (34.48%)reference16/37 (43.24%)OR: 1.4476,
95% CI: 0.5301–3.9535,
Z: 0.722
p = 0.4705
8/18 (44.4%)OR: 1.52,
95% CI: 0.4558–5.0691,
Z: 0.681
p = 0.4956
190/29 (0%)reference0/37 (0%)OR: 0.7867,
95% CI: 0.0152–40.8381,
Z: 0.119
p = 0.8175
0/18 (0%)OR: 1.5946,
95% CI: 0.0303–83.8879,
Z: 0.231
p = 0.9052
2010/29 (34.48%)reference12/37 (32.43%)OR: 1.2091,
95% CI: 0.3575–4.0887,
Z: 0.305
p = 0.8608
7/18 (38.89%)OR: 0.912,
95% CI: 0.3257–2.5536,
Z: 0.175
p = 0.76
2120/29 (69%)reference23/37 (62.16%)OR: 0.7393,
95% CI: 0.2640–2.0702,
Z: 0.575
p = 0.5653
10/18 (55.56%)OR: 0.5625,
95% CI: 0.1664–1.9013,
Z: 0.926
p = 0.3545
220/29 (0%)reference0/37 (0%)OR: 0.7867,
95% CI: 0.0152–40.8381,
Z: 0.119
p = 0.8175
1/18 (5.56%)OR: 0.5619,
95% CI: 0.0217–14.5621
Z: 0.347
p = 0.7285
231/29 (3.45%)reference0/37 (0%)OR: 0.2533,
95% CI: 0.0099–6.4525,
Z: 0.831
p = 0.4058
0/18 (0%)OR: 0.5135,
95% CI: 0.0198–13.2931,
Z: 0.401
p = 0.6881
Table 3. Chi-square test (χ2) results comparing the distribution of questionnaire responses across study groups.
Table 3. Chi-square test (χ2) results comparing the distribution of questionnaire responses across study groups.
Parameter/QuestionΧ2 CTRL vs. Breast CancerΧ2 CTRL vs. Reproductive System CancerΧ2 Breast Cancer vs. Reproductive System Cancer
Hypertension Χ2 = 2.2719
DF = 1
p = 0.1317
Χ2 = 0.0042
DF = 1
p = 0.9482
Χ2 = 1.5188
DF = 1
p = 0.2178
1Χ2 = 0.2132
DF = 1
p = 0.6443
Χ2 = 0.2132
DF = 1
p = 0.6443
Χ2 = 0.7413
DF = 1
p = 0.3892
2Χ2 = 1.363
DF = 1
p = 0.243
Χ2 = 0.0708
DF = 1
p = 0.7902
Χ2 = 1.8243
DF = 1
p = 0.1768
3Χ2 = 0.0969
DF = 1
p = 0.7556
Χ2 = 0.3202
DF = 1
p = 0.5715
Χ2 = 38.2963
DF = 1
p < 0.0001
4Χ2 = 2.2293
DF = 1
p = 0.1354
Χ2 = 0.1136
DF = 1
p = 0.736
Χ2 = 2.4953
DF = 1
p = 0.1142
5Χ2 = 0.6490
DF = 1
p = 0.4205
Χ2 = 0.6490
DF = 1
p = 0.0531
Χ2 = 7.6914
DF = 1
p = 0.0055
6Χ2 = 3.2002
DF = 1
p = 0.0736
Χ2 = 0.3623
DF = 1
p = 0.5473
Χ2 = 0.8960
DF = 1
p = 0.3438
7Χ2 = 1.3852
DF = 1
p = 0.2392
Χ2 = 0.0757
DF = 1
p = 0.7832
Χ2 = 0.5321
DF = 1
p = 0.4657
8Χ2 = 1.3852
DF = 1
p = 0.2392
Χ2 = 0.3623
DF = 1
p = 0.5473
Χ2 = 0.896
DF = 1
p = 0.3438
9---
10Χ2 = 0.6252
DF = 1
p = 0.4291
Χ2 = 0.8467
DF = 1
p = 0.3575
Χ2 = 0.0745
DF = 1
p = 0.7849
11Χ2 = 0.0939
DF = 1
p = 0.7593
Χ2 = 1.1534
DF = 1
p = 0.2828
Χ2 = 0.7408
DF = 1
p = 0.3894
12Χ2 = 1.5921
DF = 1
p = 0.2070
Χ2 = 1.6111
DF = 1
p = 0.2043
Χ2 = 0.0005
DF = 1
p = 0.9818
13Χ2 = 4.0456
DF = 1
p = 0.0443
Χ2 = 0.0129
DF = 1
p = 0.9095
Χ2 = 3.5599
DF = 1
p = 0.0592
14Χ2 = 0.2132
DF = 1
p = 0.6443
Χ2 = 0.6477
DF = 1
p = 0.4209
Χ2 = 1.5545
DF = 1
p = 0.2125
15Χ2 = 0.0011
DF = 1
p = 0.974
Χ2 = 0.0702
DF = 1
p = 0.791
Χ2 = 0.0618
DF = 1
p = 0.8037
16Χ2 = 0.3413
DF = 1
p = 0.5591
Χ2 = 2.7816
DF = 1
p = 0.0954
Χ2 = 0.4865
DF = 1
p = 0.4855
17Χ2 = 3.7408
DF = 1
p = 0.0531
Χ2 = 0.1645
DF = 1
p = 0.6851
Χ2 = 4.1462
DF = 1
p = 0.0417
18Χ2 = 0.5147
DF = 1
p = 0.4731
Χ2 = 0.4565
DF = 1
p = 0.4993
Χ2 = 0.007
DF = 1
p = 0.9334
19---
20Χ2 = 0.0303
DF = 1
p = 0.8618
Χ2 = 0.0914
DF = 1
p = 0.7624
Χ2 = 0.2192
DF = 1
p = 0.6397
21Χ2 = 0.3264
DF = 1
p = 0.5678
Χ2 = 0.8467
DF = 1
p =0.3575
Χ2 = 0.2162
DF = 1
p = 0.6419
22-Χ2 = 1.6111
DF = 1
p = 0.2043
Χ2 = 2.0556
DF = 1
p = 0.1517
23Χ2 = 1.2759
DF = 1
p = 0.2587
Χ2 = 0.6207
DF = 1
p = 0.4308
-
Table 4. Statistical comparison of serum BPA levels between study groups. Due to non-normal distribution (Shapiro–Wilk test), group comparisons were performed using non-parametric Mann–Whitney U tests. Ns—no significance.
Table 4. Statistical comparison of serum BPA levels between study groups. Due to non-normal distribution (Shapiro–Wilk test), group comparisons were performed using non-parametric Mann–Whitney U tests. Ns—no significance.
BPAMean [pg/mL]95% CI of Diff.Significancep-Value
CTRL vs. breast cancer28,191.2 vs. 49,136(−79,375 to 37,485)Ns0.877
CTRL vs. reproductive system cancer28,191.2 vs. 95,883.4(−132,721 to −2664)Yes0.045
Breast cancer vs. reproductive system cancer49,136 vs. 95,883.4(−108,081 to 14,586)Ns0.0884
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Derkaczew, M.; Zglejc-Waszak, K.; Dabrowski, L.; Kocik, J.; Zdaniukiewicz, A.; Thoene, M.; Jozwik, M.; Gonkowski, S.; Wojtkiewicz, J. An Analysis of the Role of Bisphenol A in Breast and Reproductive-System Cancers. J. Clin. Med. 2025, 14, 4706. https://doi.org/10.3390/jcm14134706

AMA Style

Derkaczew M, Zglejc-Waszak K, Dabrowski L, Kocik J, Zdaniukiewicz A, Thoene M, Jozwik M, Gonkowski S, Wojtkiewicz J. An Analysis of the Role of Bisphenol A in Breast and Reproductive-System Cancers. Journal of Clinical Medicine. 2025; 14(13):4706. https://doi.org/10.3390/jcm14134706

Chicago/Turabian Style

Derkaczew, Maria, Kamila Zglejc-Waszak, Lukasz Dabrowski, Janusz Kocik, Adam Zdaniukiewicz, Michael Thoene, Marcin Jozwik, Slawomir Gonkowski, and Joanna Wojtkiewicz. 2025. "An Analysis of the Role of Bisphenol A in Breast and Reproductive-System Cancers" Journal of Clinical Medicine 14, no. 13: 4706. https://doi.org/10.3390/jcm14134706

APA Style

Derkaczew, M., Zglejc-Waszak, K., Dabrowski, L., Kocik, J., Zdaniukiewicz, A., Thoene, M., Jozwik, M., Gonkowski, S., & Wojtkiewicz, J. (2025). An Analysis of the Role of Bisphenol A in Breast and Reproductive-System Cancers. Journal of Clinical Medicine, 14(13), 4706. https://doi.org/10.3390/jcm14134706

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop